As of 2026-03-21, the Relative Valuation of Arrowhead Pharmaceuticals Inc (ARWR) is 20.52 USD. This relative valuation is based on P/E multiples. With the latest stock price at 56.33 USD, the upside of Arrowhead Pharmaceuticals Inc based on Relative Valuation is -63.6%.
The range of the Relative Valuation is 9.63 - 40.91 USD.
| Range | Selected | |
| Trailing P/E multiples | 11.9x - 28.3x | 20.2x |
| Forward P/E multiples | 19.8x - 25.6x | 24.3x |
| Fair Price | 9.63 - 40.91 | 20.52 |
| Upside | -82.9% - -27.4% | -63.6% |
| Date | P/E |
| 2026-03-13 | 38.11 |
| 2026-03-12 | 38.08 |
| 2026-03-11 | 40.22 |
| 2026-03-10 | 40.98 |
| 2026-03-09 | 42.00 |
| 2026-03-06 | 41.41 |
| 2026-03-05 | 44.03 |
| 2026-03-04 | 45.07 |
| 2026-03-03 | 44.38 |
| 2026-03-02 | 44.54 |
| 2026-02-27 | 43.80 |
| 2026-02-26 | 43.89 |
| 2026-02-25 | 42.66 |
| 2026-02-24 | 44.08 |
| 2026-02-23 | 43.71 |
| 2026-02-20 | 44.02 |
| 2026-02-19 | 44.21 |
| 2026-02-18 | 44.57 |
| 2026-02-17 | 44.09 |
| 2026-02-13 | 44.18 |
| 2026-02-12 | 43.19 |
| 2026-02-11 | 42.61 |
| 2026-02-10 | 43.56 |
| 2026-02-09 | 43.37 |
| 2026-02-06 | 44.67 |
| 2026-02-05 | 44.75 |
| 2026-02-04 | 47.12 |
| 2026-02-03 | 49.94 |
| 2026-02-02 | 50.54 |
| 2026-01-30 | 48.00 |
| 2026-01-29 | 47.85 |
| 2026-01-28 | 45.40 |
| 2026-01-27 | 46.32 |
| 2026-01-26 | 46.26 |
| 2026-01-23 | 46.42 |
| 2026-01-22 | 48.18 |
| 2026-01-21 | 46.80 |
| 2026-01-20 | 45.19 |
| 2026-01-16 | 44.20 |
| 2026-01-15 | 45.87 |
| 2026-01-14 | 45.63 |
| 2026-01-13 | 45.38 |
| 2026-01-12 | 45.64 |
| 2026-01-09 | 44.70 |
| 2026-01-08 | 45.00 |
| 2026-01-07 | 45.48 |
| 2026-01-06 | 49.02 |
| 2026-01-05 | 44.22 |
| 2026-01-02 | 46.93 |
| 2025-12-31 | 45.96 |